Free Trial

Jefferies Financial Group Begins Coverage on Cybin (NASDAQ:HELP)

Key Points

  • Jefferies Financial Group initiated coverage on Cybin with a "buy" rating and a $22 price target, implying about a 232% upside from the prior close.
  • Shares opened at $6.62 (down ~2.2%), with a market cap of $330.3 million, a negative P/E of -1.70, and a 52-week range of $4.81 to $10.72.
  • Cybin is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics and novel small-molecule analogs for treating mental health disorders.
  • Five stocks we like better than Cybin.

Equities researchers at Jefferies Financial Group assumed coverage on shares of Cybin (NASDAQ:HELP - Get Free Report) in a report issued on Monday. The firm set a "buy" rating and a $22.00 price target on the stock. Jefferies Financial Group's target price would suggest a potential upside of 232.33% from the stock's previous close.

Cybin Stock Down 2.2%

NASDAQ:HELP opened at $6.62 on Monday. The company has a market cap of $330.27 million, a price-to-earnings ratio of -1.70 and a beta of 0.63. Cybin has a fifty-two week low of $4.81 and a fifty-two week high of $10.72. The company has a current ratio of 8.58, a quick ratio of 8.58 and a debt-to-equity ratio of 0.21.

Cybin Company Profile

(Get Free Report)

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines